Alethia Biotherapeutics has entered into a global strategic alliance with the International Biotech Center Generium (IBC Generium) to jointly develop AB-16B5, a monoclonal antibody (MAb) inhibitor of epithelial-to-mesenchymal transition. Under the terms of the alliance, Alethia and IBC Generium will collaborate on the ongoing development of AB-16B5 and, upon completion of the initial clinical study, share equally in the downstream economics in territories outside Russia and the CIS states. Alethia will receive an up-front cash payment and R&D funding to conduct the initial clinical study in Canada. In addition to an exclusive licence granted to IBC Generium for other territories, IBC Generium has also been granted the right to an exclusive licence for Russia and the CIS states for which development milestones and royalties would be payable to Alethia. Further financial terms were not disclosed.
|Agreement Status:||New||Date Announced:||29 May 2013|
|Date Last Reported:||Duration:|
|Est Total Value:||Investment To Date:|
|Generic / Brand Name:||AB-16B5|
|Therapeutic Area:||Antineoplastic and Immunomodulating Agents|